

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Quinox 60.6 mg/g Premix for Medicated Feeding Stuff for Sheep and Cattle

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each g contains

Active substance:

Decoquinatate60.6 mg

Excipient:

Qualitative composition of excipients and other constituents
Wheat flour
Hydrated colloidal silica
Soya bean oil, refined

White to off-white fine powder without agglomerates.

3. CLINICAL INFORMATION

3.1 Target species

Sheep (lambs) and cattle (calves).

3.2 Indications for use for each target species

For the treatment and metaphylaxis of coccidiosis in lambs and calves during coccidial challenge.

The presence of the disease in the group or flock must be established before the veterinary medicinal product is used.

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

3.4 Special warnings

The use of the veterinary medicinal product will maintain normal growth under conditions of coccidial challenge but does not improve growth of healthy lambs or calves.

It is recommended to treat all animals in a pen.

Coccidiosis is an indicator of insufficient hygiene in the flock/pen. It is recommended to improve concomitantly the hygienic conditions in the concerned facility, particularly dryness and cleanliness.

To alter the course of an established clinical coccidial infection, in individual animals already showing signs of diarrhoea, additional supportive therapy may be required.

Unnecessary use of antiparasitics or use deviating from the instructions given in the SPC may increase the resistance selection pressure and lead to reduced efficacy. The decision to use the product should be based on confirmation of the parasitic species and burden, or of the risk of based on its epidemiological features, for each individual animal/herd.

Therapy should be based on epidemiological information and knowledge of susceptibility of the target pathogens at farm level, or at local/regional level. Use of the veterinary medicinal product should be in accordance with official, national and regional antimicrobial policies.

As with any antiparasiticide frequent and repeated use of antiprotozoals from the same class may lead to the development of resistance. If resistance is present it should be considered to use another antiprotozoal from another class and with a different mechanism of action.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This veterinary medicinal product may be harmful in case of hand-to-mouth contact. Avoid accidental ingestion.

Do not smoke, eat or drink while handling the veterinary medicinal product.

Personal protective equipment consisting of protective gloves should be worn when handling the veterinary medicinal product.

Wash hands after use.

In case of accidental ingestion, seek medical advice and show the package leaflet or the label to the physician

Other precautions:

This product is only authorised for use in medicated feedingstuffs or premixtures.

In both cases it must be thoroughly mixed with feedingstuffs materials to ensure it is evenly distributed throughout the mixture.

Any premixture containing this product must be thoroughly mixed with feedingstuffs materials to ensure that is evenly distributed throughout the final feed.

Special precautions for the protection of the environment

Not applicable

3.6 Adverse events

Sheep (lambs), cattle (calves):
None known.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy:

Can be used during pregnancy.

Lactation:

Can be used during lactation.

3.8 Interaction with other medicinal products and other forms of interaction

Do not mix with or into feeds containing any other anti-coccidial product.

3.9 Administration routes and dosage

In-feed use.

Species and indication	Method of administration	Recommended dose level	Recommended duration of treatment
Treatment of coccidiosis in lambs and calves and metaphylaxis of coccidiosis in lambs	In lamb and calf feed	1 mg decoquinate/kg bodyweight daily	28 days
Metaphylaxis of coccidiosis in calves	In calf	0.5 mg decoquinate/kg bodyweight daily	28 days

To ensure a correct dosage, bodyweight should be determined as accurately as possible. For all species, the consumption of the medicated feed may depend of the clinical condition of the animals. In order to guarantee a correct dosing, the concentration of the veterinary medicinal product in the feed should be adjusted accordingly.

The use of suitably calibrated measuring equipment is recommended.
Partly consumed feed must be disposed of with other waste feed and not given to other animals.

The following formula is recommended:

$$\frac{\text{Kg Quinox 60.6 mg/g Premix/T feed} \times \text{Dose (mg active ingredient/kg body weight) x Total weight of the animals to be treated (kg)}}{\text{Daily feed intake (kg) x 60}}$$

Mixing Instructions: To help obtain even distribution in the final feed, it is recommended first to mix thoroughly at the rate of 1 part of the product to 3 parts of feed before blending into the final mix. In the preparation of pelleted feed, preconditioning temperatures of up to 105°C and relative humidity of a 100% for 15 minutes have been used and shown to have no effect on the product.

A manufacturer authorised to incorporate at levels below 2 kg per tonne must be responsible for mixing when incorporation is less than 2 kg per tonne of final feed. For infections with coccidia, the need for and frequency of re-treatment(s) should be based on professional advice and should take into account the local epidemiological situation and the animal's lifestyle.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Overdosage is unlikely with in-feed medication. Decoquinate dosages of 4 mg/kg bodyweight in sheep and lambs and 6 mg/kg bodyweight in calves have been found to be well tolerated and without observable side effects.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Do not use for prophylaxis.

This veterinary medicinal product is intended to be used for the preparation of medicated feed.

3.12 Withdrawal periods

Cattle and sheep:
Meat and offal: zero days.

Milk: Not authorised for use in animals producing milk for human consumption.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QP51BX04

4.2 Pharmacodynamics

Decoquinate belongs to the quinolone group of coccidiostats. It has an anti-coccidial action, interfering with the electron transport in the mitochondrial cytochrome system. Decoquinate acts early in the life cycle of *Eimeria* on sporozoites, released from ingested oocysts and on first-generation meronts, arresting development and release of merozoites and thus preventing further damage to the intestines.

4.3 Pharmacokinetics

The drug is administered by the oral route, the main site of action being within the gastro-intestinal tract. It is poorly absorbed by the target species and is largely eliminated in faeces unchanged. Consequently, tissue residues are low and deplete rapidly with time. Recovery of the administered material via excretion is essentially complete.

Environmental properties

Decoquinate is very persistent in soil.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf life after first opening the immediate packaging:

0.833 kg bag: 3 months

5 kg bag: 6 months

Shelf-life after incorporation into feed: 6 months

5.3 Special precautions for storage

This veterinary medicinal product does not require any special temperature storage conditions.

5.4 Nature and composition of immediate packaging

0.833 kg heat-sealed zip bag made of polyethylene/polyamide/aluminium/polyester

5 kg heat-sealed bag made of polyethylene/aluminium/polyamide

Not all pack sizes may be marketed

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Huvepharma NV

7. MARKETING AUTHORISATION NUMBER

Vm 30282/5030

8. DATE OF FIRST AUTHORISATION

07 August 2026

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

August 2026

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

Gavin Hall
Approved: 18 August 2026